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Glucan particles (GPs) are hollow, porous 3–5 𝜇m microspheres derived from the cell walls of Baker’s yeast (Saccharomyces
cerevisiae).The 1,3-𝛽-glucan outer shell provides for receptor-mediated uptake by phagocytic cells expressing 𝛽-glucan receptors.
GPs have been used for macrophage-targeted delivery of a wide range of payloads (DNA, siRNA, protein, small molecules, and
nanoparticles) encapsulated inside the hollow GPs or bound to the surface of chemically derivatized GPs. Gallium nanoparticles
have been proposed as an inhibitory agent against HIV infection. Here, macrophage targeting of gallium using GPs provides for
more efficient delivery of gallium and inhibition of HIV infection in macrophages compared to free gallium nanoparticles.
1. Introduction
Efficient targeted drug delivery systems are paramount for the
development of novel and effective biopharmaceuticals and
diagnostic agents. The advantages of targeted drug delivery
and release include increased drug concentrations at the site
of disease, limited side effects fromoff-target cell damage, and
reduction in dose frequency and cost and length of treatment.
A primary challenge for the development of drug delivery
systems is the lack of optimal strategies to achieve selective
and efficient cellular targeting.
Glucan particles (GPs) derived from Baker’s yeast have
been efficiently used for targeted payload delivery to
macrophages and dendritic cells [1–11]. The hollow and
porous nature of GPs (3–5𝜇m in diameter) allows for
absorption and retention of payload molecules. The 𝛽-1,3-D
glucan surface composition also serves as an effective means
of recognition by cell surface receptors in macrophages
(via dectin-1 (D1) and Complement Receptor 3 (CR3))
and other phagocytic innate immune cells, allowing for a
receptor-mediated particle uptake mechanism [3, 12]. We
have reported several methods for efficient encapsulation of
a wide range of molecules inside GPs [1–11]. Water soluble
macromolecules (e.g., DNA, siRNA, and proteins) can be
efficiently encapsulated inside GPs by both polyplex and
layer-by-layer (LbL) synthetic approaches [1, 2]. Neutral,
small drug molecules have been encapsulated by embedding
the payload in polymer hydrogels [7] and encapsulation
within small nanoparticles prepared in situ inside GPs or
loaded onto the surface of GPs in a piggyback approach
[6]. These different drug loading strategies accomplish two
important goals: (1) high encapsulation efficiency of the
payloadmolecule using a synthetic approach thatwill provide
protection of the payload inside GP during storage and in
transit to macrophages and (2) efficient, sustained release at
low pH (pH 5 or lower) to achieve payload escape from the
GPs in the endosomal compartment following macrophage
uptake. Here we describe a potential new application of GPs
for macrophage-targeted delivery of gallium for enhanced
inhibition of HIV infection in human macrophages com-
pared to free gallium nanoparticles.
Gallium has been shown to be effective in the treatment
of several disorders, including viral and bacterial infections
[13]. Gallium salts are used in pharmaceutical applications
for hypercalcemia, and there is also evidence of a gal-
lium therapeutic effect against syphilis, trypanosomiasis, and
tuberculosis [14]. Gallium’s therapeutic activity stems from
its similarity to iron (III), with the ability to substitute for
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iron (III) and interfere with critical enzymatic process in
metabolism and the growth of proliferating cells due to
the inability of gallium (III) to be reduced in redox-active
enzymes [15]. This interference is responsible for gallium
inhibition of proliferation of several pathogenic microorgan-
isms, most notably species of Mycobacterium. Cell uptake of
gallium-transferrin complexes by infected cells, particularly
macrophages, diminishes iron (III) concentration essential to
enzymes likely to be involved in various processes critical for
viral and bacterial infection. Additionally, gallium’s lack of
redox activity reduces potential toxicity effects from gallium
as it does not interfere with iron (II) bearing molecules, such
as heme, or with oxygen transport. Gallium is also resistant
to drug efflux pumps, allowing it to be less vulnerable to drug
resistance mechanisms.
Recently, gallium nanoparticles have been proposed as
an inhibitory agent against coinfection with human immun-
odeficiency virus (HIV) and Mycobacterium tuberculosis
(TB) [16]. Nanoparticles of gallium (III) mesotetraphenyl-
porphyrin chloride delivered to macrophages provided a
long acting effect against HIV and HIV-TB coinfection.
A limitation of this system was the inefficient targeting
of the proposed particles to macrophages, thus requiring
large concentrations of gallium for sustained effect on HIV
inhibition.
In this publication we describe an effective approach for
the encapsulation of gallium compounds in the form of large
nanoparticle aggregates inside GPs. This approach provides
for efficient cell targeting of gallium into macrophages by
receptor-mediated uptake of GP. Macrophages are a major
cellular target for HIV in tissues. For example, perivascular
macrophages in brain tissue are heavily infected in subjects
with HIV associated dementia [17]. The selected gallium
compounds are insoluble at pH 7, but they react in the
acidic endosomal compartment upon GP mediated cell
uptake leading to release of water soluble gallium (III). This
approach represents an effective strategy for the encapsula-
tion and macrophage-targeted delivery of gallium that could
be extended to other classes of inorganic nanoparticulate
materials.
2. Materials and Methods
2.1. Materials. Glucan particles were prepared from Fleish-
mann’s Baker’s yeast (ABMauri Food Inc., Chesterfield, MO)
as previously described [1]. Gallium (III) chloride (99.999%
purity) was purchased fromAlfa Aesar. All reagents, solvents,
and buffer solutions for the syntheses and characterization
of gallium particles were purchased from Sigma-Aldrich and
used without further purification. Tissue culture materials
were purchased from Gibco.
2.2. Synthesis of Gallium Nanoparticles Inside Glucan Particles
(GP-Ga Formulations). Gallium chloride was absorbed into
GPs by swelling a dry GP pellet (5mg) in a subhydrodynamic
volume (5 𝜇L/mg GP) of an aqueous gallium chloride solu-
tion. GP samples containing gallium chloride were incubated
at room temperature for 1 hour to allow for diffusion into the
GPs. The loaded GPs were then lyophilized and the loading
and lyophilization steps repeated until target concentrations
of gallium chloride within the GP samples were achieved.
The dry GP-GaCl3 pellets were then treated by wetting
the pellets in a subhydrodynamic volume of trapping agent
solution (sodium hydroxide, sodium bicarbonate, or sodium
triphosphate) to produce insoluble gallium nanoparticles
inside GPs.TheGP-Ga particles were thenwashed with water
to remove unreacted gallium chloride or small (<30 nm)
gallium nanoparticles not trapped inside GPs. Samples were
finally sterilized overnight in 70% ethanol and aseptically
washed in 0.9% saline, and GP number was counted with a
hemocytometer. Sample concentrationswere then adjusted to
1 × 108 particles/mL in 0.9% saline and stored frozen.
2.3. Characterization of Glucan Particle Encapsulated
Gallium Nanoparticles (GP-Ga)
2.3.1. Trapping Efficiency of Gallium in GP-Ga Formulations.
Gallium was quantified using a spectrofluorometric assay
[18]. Samples containing GP-Ga and empty GPs (negative
controls) were suspended in 6M HCl. Samples were cen-
trifuged and the supernatants containing extracted gallium
were mixed with rhodamine B solution in 6M HCl (2mg
rhodamine B/mL) and incubated for 10 minutes at room
temperature. The gallium-rhodamine B complexes were
extracted with benzene. The fluorescence of the complexes
in the organic phase was measured at an excitation wave-
length of 553 nm and emission wavelength of 608 nm. GP-
Ga samples incubated in aqueous rhodamine B solution were
also prepared for fluorescencemicroscopy analysis to confirm
formation of Ga-rhodamine complexes inside GPs.
2.3.2. Kinetics of Gallium Release from GP-Ga. Samples con-
taining 1mg of GP-Ga were incubated in 1mL of phosphate
buffer saline (PBS, pH 7) or in 0.1M sodium acetate buffer
(pH 5). The samples were incubated at 37∘C for a total of 4
days. At specific times, 100𝜇L was aliquoted from samples
and fresh buffer was added to maintain sink conditions.
Galliumwas quantified in these aliquots using the rhodamine
B fluorescence assay as described above.
2.3.3. GP-Ga Cytotoxicity. To determine the effect of gallium
on cell growth and viability, GP-Ga samples and empty GP
controls were evaluated in a B6 immortalizedmurine derived
bonemarrowmacrophage (iMac) cell line [19]. Particles were
evaluated for particle cell uptake at a 10 : 1 GP : cell ratio to
maximize phagocytic cell uptake. Free gallium nanoparticles
were also evaluated in the same concentration range as GP-
Ga formulations on a gallium weight basis. Samples were
suspended in complete DMEM and added to 96-well plates
containing 1 × 104 cells/well. The plates were incubated at
37∘C under 5% CO2 for 24 h. Alamar blue (10𝜇L) was added,
incubated at 37∘C for 30min, and fluorescence was measured
(excitation wavelength = 530 nm, emission wavelength =
590 nm). Fluorescence response is dependent on the reduc-
tion of the Alamar blue indicator by metabolically active cells
and is a measure of cell number and viability. Growth arrest
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Figure 1: Schematic representation of gallium loading into GPs and trapping reaction to form gallium nanoparticles inside GPs. Microscopy
images show complexes of rhodamine B with gallium trapped inside GPs (right image); minimum background fluorescence was observed
from empty GPs (left).
was calculated from the fluorescence response of the sample
relative to the response of control wells containing buffer
(PBS) or empty GPs.
2.4. HIV Infected Human Macrophage Assay to Assess Inhibi-
tion of HIVReplication. Cotransfections of 293T/17 cells with
env-minus NL4.3 backbone, pHIVec2/GFP reporter, and
different envelope plasmids (Env17, B33, or B59) in pSVIIIenv
were done with a CaCl2 Promega Profection Kit (Promega
Corporation, Madison, WI) [20]. Virus in supernatants was
harvested 48 hours after transfection. Supernatants were
collected and spun down at 1200 rpm for 5 minutes and
1mL aliquots were made and frozen. Infectivity of each Env+
pseudovirus was estimated as GFP+ focus forming units via
titration on HeLa TZM-BL cells [21].
Human monocyte derived macrophages were isolated
and cultured using processed buffy coats from New York
Biologics Inc. Briefly, 5×107 Ficoll-purified peripheral blood
mononuclear cells (PBMC) from a buffy coat were plated
into 15 cm bacterial culture dishes for 3 h before extensively
washing away nonadherent cells, culturing overnight, and
repeating the washes. The adherent monocytes were then
cultured for 5–7 days in 10% AB+ human plasma in DMEM.
The differentiated macrophages were treated with EDTA and
transferred to 48-well tissue culture dishes the day prior
to infection (day −1) at 1.25 × 105 cells/well. Cells were
allowed to settle and adhere. After that, cells were treated
with single (day −1) or multiple (days −1, 1, and 3) doses of
different types of GP-Ga2(CO3)3 formulations, empty GPs,
or free Ga2(CO3)3 nanoparticles. On day 0, all wells were
infectedwithHIVEnv+ pseudovirus carrying aGFP reporter
gene following a laboratory standard protocol: 100 𝜇L/well
(20𝜇g/mL) DEAE dextran for 30 minutes at 37∘C. HIV Env+
pseudoviruses were diluted 1 : 2 and added at 100 𝜇L/well and
then spinoculated at 1200 rpm for 45 minutes. On Day 7, cells
were imaged and infected GFP-positive cells were counted
using a fluorescent microscope at 20x magnification. Percent
infection was calculated with B33 Env+ pseudovirus alone
as the 100% infected value. The assay was repeated twice to
confirm trends and values. Controls were done with HIV
reverse transcriptase inhibitor Zidovudine (AZT) given in
multiple doses similar to the gallium formulations (20, 10, and
5 𝜇M).
3. Results
3.1. Synthesis of GP-Ga Formulations. A schematic represen-
tation of gallium loading and trapping inside GPs is shown
in Figure 1. Dry GPs were swelled in a subhydrodynamic
volume of a gallium chloride solution to load GPs by
diffusion of the gallium solution into the particles through the
porous structure of the glucan particle surface. The particles
were then lyophilized and the loading cycle was repeated
until achieving target gallium chloride concentrations inside
GPs. Finally, the dry GP-GaCl3 particles were swollen in a
subhydrodynamic volume of a solution containing a suitable
reagent for a rapid displacement reaction to produce insol-
uble gallium oxide (Ga2O3), gallium phosphate (GaPO4),
or gallium carbonate (Ga2(CO3)3) nanoparticles inside GPs.
Excess reagents and small (<30 nm) insoluble gallium salts
were washed from the GP samples during purification and
sterilization in 70% ethanol. It is likely that thewater insoluble
galliummaterials trapped inside GPs correspond to mixtures
of compounds. For example, the reaction of gallium chloride
with sodium hydroxide produces gallium oxide (Ga2O3) and
it has been reported to produce other gallium compounds
such as amorphous Ga(OH)3 and crystalline 𝛼-GaOOH [22].
Free gallium nanoparticles were also synthesized under the
same stoichiometric conditions employed in the synthesis of
gallium nanoparticles inside GPs. The objective of this work
was to compare the effect of GP encapsulated gallium and
free gallium nanoparticles on HIV infectivity inhibition in
human macrophages. Future work will focus on complete
characterization of the gallium materials in the most active
GP-Ga formulation.
3.2. Characterization of GP-Ga Formulations
GalliumEncapsulation inGPs.The amount of gallium trapped
inside GPs was quantified using a spectrofluorometric assay
with rhodamine B. GP-Ga samples were digested in 6M
HCl to generate soluble gallium chloride. Gallium in acidic
medium forms a stable complex with rhodamine B with
higher solubility in organic solvents such as benzene. Fluo-
rescencemeasurements of the gallium-rhodamine B complex
extracted into benzene allowed for direct quantification of the
concentrations of gallium trapped in GPs (Table 1). Figure 2
shows these quantitative results as percentage of gallium
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Figure 2: Efficiency of gallium trapping in glucan particles follow-
ing reaction of gallium chloride inside GPs to yield the correspond-
ing encapsulated water insoluble nanoparticulate gallium salt.
Table 1: Target and measured concentration of gallium trapped in
glucan particles.
Target concentration
𝜇g Ga/mg GP
Measured concentration 𝜇g Ga/mg
GP ± SD
Ga2O3 Ga2(CO3)3 GaPO4
40 26 ± 9 26 ± 12 25 ± 10
100 47 ± 16 108 ± 36 77 ± 18
200 90 ± 38 150 ± 28 140 ± 25
400 175 ± 38 355 ± 49 141 ± 26
2000 1063 ± 347 1308 ± 49 1085 ± 145
trapped in GPs relative to the target amount of gallium
chloride loaded in GPs. Gallium carbonate was trappedmore
efficiently (>65% trapping at all target concentrations) than
gallium oxide or phosphate. Additionally, Figure 1 shows
fluorescent microscopy image of a GP-Ga2(CO3)3 sample
treated with rhodamine B confirming the trapping of the
gallium salt as insoluble cores inside the hollow space of the
glucan particles.
GP-Ga Cytotoxicity. We have previously shown that empty
GPs and GPs encapsulating nanoparticles are nontoxic to
cells at particle : cell ratios of up to 33 : 1 particle/cell [6].
We examined cytotoxicity of GP-Ga formulations by adding
GP-Ga to the murine B6 macrophage cells at a ratio of
10 : 1 GP : cell and free Ga nanoparticles at an equivalent Ga
concentration. The samples were incubated for 18–24 hours
and cell viability was assessed using the Alamar blue viability
assay. The results showed greater than 85% cell viability
with all GP-Ga and free Ga nanoparticles formulations (not
shown).
Kinetics of Ga Release from GP-Ga Formulations. The GP-
Ga formulations were characterized for the effect of pH on
kinetics of gallium release. The selection criteria for optimal
GP-Ga formulations were stable formulations at pH 7 and
sustained release at pH 5 (endosomal pH). Release kinetic
results (Figure 3) show both GP-Ga2O3 and GP-Ga2(CO3)3
are highly stable at pH 7 (<10% Ga released after four days
of incubation at 37∘C). The GP-GaPO4 formulation showed
a burst release of ∼20% gallium and stability after the initial
burst release.This burst release indicates that the galliumwas
not efficiently trapped as phosphate as gallium phosphate is
water insoluble at pH 7. All formulations showed sustained
gallium release at pH5with faster release forGaPO4, followed
by Ga2(CO3)3, and slower release rate for Ga2O3. All samples
released gallium efficiently at pH<3 (data not shown) due to a
fast reaction under harsh acidic conditions to generate soluble
gallium chloride.
GP-Ga2(CO3)3 formulations were selected for HIV infec-
tion studies based on results showing higher efficiency of Ga
trapping, stability at pH 7, and better sustained release at pH
5 than GP-Ga formulations of gallium oxide or phosphate.
3.3. Effect of GP-Ga Treatment on HIV Infection of Human
Macrophages. Wehave previously demonstrated that GPs are
effectively phagocytosed by macrophage cells via a receptor-
mediated mechanism [3]. Experimental results with fluo-
rescein labeled glucan particles using murine macrophages
and dectin-1 knock-out murine macrophages demonstrated
the role of the dectin-1 receptor for efficient particle uptake.
The addition of a soluble beta-glucan receptor antagonist
(laminarin) blocks uptake of GPs which also demonstrates
that uptake occurs via a receptor-mediated mechanism. In
this study, we used fluorescein labeled empty GPs (f-GP) to
show that humanmacrophages are also capable of GP uptake.
The fluorescent image in Figure 4 demonstrates efficient
particle uptake by the primary human macrophages used in
the HIV inhibition assays.
3.4. HIV Inhibition in Human Primary Macrophages with
GP-Ga and Free Ga Nanoparticles. We next tested whether
GP-Ga formulations could inhibit HIV infection of primary
human macrophages. We selected GP-Ga2(CO3)3 particles
to investigate, since Ga2(CO3)3 was trapped more efficiently
compared to Ga2O3 or GaPO4 (Figure 2). In addition, the
profiles of gallium retention at pH 7 and release at pH
5 for GP-Ga2(CO3)3 were superior to other formulations.
Two different GP-Ga2(CO3)3 dosing strategies were tested
for their capacity to inhibit HIV-1 pseudovirions carrying
R5 macrophage-tropic B33 envelope glycoproteins (Envs)
[23, 24]. Macrophages were treated with GP-Ga2(CO3)3
containing increasing amounts of Ga either in a single dose
the day before infection (Day −1 dose) or 1 day before
infection with additional doses 1 and 3 days after infection
(Days −1, 1, and 3 dose). Increasing doses of GP-Ga2(CO3)3
increased the efficiency of inhibition, with the three-dose
strategy superior to a single dose (Table 2). Inhibition reached
93–95%, although complete blockade was not observed.
We next compared GP-Ga2(CO3)3 to free Ga2(CO3)3 as
nanoparticles (Ga2(CO3)3 NPs). It was previously reported
that gallium in the form of gallium mesotetraporphyrin
Journal of Drug Delivery 5
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Figure 3: Release kinetics of gallium from GPs up to 96 hours at pH 7 (a) and pH 5 (b).
(a) (b)
Figure 4: Fluorescent photomicrographs showing efficient uptake of fluorescein labeled glucan particles by human macrophages (a). No
significant autofluorescence was detected from control cells (b) when exposed to UV light for same exposure time as cells treated with f-GPs.
nanoparticles inhibited HIV infection of macrophages [16].
Figures 5 and 6 show that GP-Ga2(CO3)3 inhibited HIV
infection of macrophages significantly more efficiently com-
pared to free Ga2(CO3)3 NPs. Of note, Figure 6 indicates that
empty glucan particles also inhibited infection, albeit only
weakly compared to GP-Ga2(CO3)3.
4. Discussion
We show here that glucan particles can deliver gallium
carbonate into primary human macrophages, where it is
released over time in the low pH of endosomes to inhibit
HIV-1 infection.
Glucan particles have been utilized for macrophage-
targeted delivery of a wide range of payloads such as DNA,
RNA, proteins, and small drug molecules [1, 2, 4–6, 11].
Gallium in the form of gallium mesotetraphenylporphyrin
nanoparticles has been recently proposed as an inhibition
agent for both HIV and TB in macrophages [16]. How-
ever, these gallium nanoparticles lack specificity to target
macrophage cells unlike glucan particles that are efficiently
targeted to macrophages by a receptor-mediated uptake
mechanism. The goals of using glucan particles as carrier of
6 Journal of Drug Delivery
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Figure 5: HIV infectivity inhibition in human macrophages fol-
lowing uptake of GP-Ga2(CO3)3 or free Ga2(CO3)3 formulations.
Results are average of three experiments ± S.D. Statistical signifi-
cance was determined by 𝑡-test; ∗𝑃 < 0.01.
Table 2: Effect of dosage on HIV inhibition of macrophages using
GPs containing gallium carbonate at different loading levels of gal-
lium. Results are the average of three experiments. Statistical signif-
icance was determined by 𝑡-test, a𝑃 < 0.05 statistical significance
between GP-Ga2(CO3)3 and GP control, and
b
𝑃 < 0.1 statistical
significance between dosing regimes.
Sample 𝜇g Ga/mg GP % HIV inhibition ± SD
Day −1 dose Days −1, 1, 3 doses
GP 0 10 ± 9 19 ± 16
GP-Ga2(CO3)3 108 45 ± 2
a 74 ± 17a
GP-Ga2(CO3)3 150 53 ± 19 92 ± 3
a
GP-Ga2(CO3)3 355 44 ± 19 91 ± 2
a,b
gallium nanoparticles are to (1) provide receptor-mediated
targeted delivery to macrophages and (2) reduce gallium
dosage as uptake of a single GP provides for delivery of larger
amounts of gallium than a free gallium nanoparticle.
We demonstrated efficient encapsulation of gallium in
GPs by loading of water soluble gallium chloride into the
particles followed by reaction with sodium salt or base
to form insoluble gallium oxide, carbonate, or phosphate
nanoparticles insideGPs (Figure 1). Efficient trapping of these
materials requires the formation of gallium nanoparticles
larger than 30 nm in diameter to prevent diffusion through
the pores of the glucan particles. Galliumwas encapsulated in
GPs at concentrations as high as 1400 𝜇gGa/mg GP as shown
in Figure 2.
We established that glucan particles loaded with
Ga2(CO3)3 had a superior combination of retention at pH
7 and release at pH 5 compared to other gallium salts. This
experiment enabled us to devise a dosing schedule to enable
Ga2(CO3)3 release into endosomes before and after HIV
infection. Using this approach, HIV inhibition of up to 95%
was achieved.
Inhibition values higher than 80% were achieved with
GP-Ga2(CO3)3 formulations containing 108 to 355𝜇gGa/mg
GP (Figure 5). Macrophage cells in these experiments were
treated at a ratio of 10GPs/cell in each dose for a total of
3×107 glucan particles per 1×106 cells for the three-day dose
treatment.The gallium concentration range added to the cells
increases from 6.5 𝜇gGa/1 × 106 cells for the 108𝜇gGa/mg
GP-Ga2(CO3)3 formulation to 21.3 𝜇gGa/1 × 10
6 cells for the
355 𝜇gGa/mg GP-Ga2(CO3)3 formulation. A previous study
with gallium nanoparticles showed HIV inhibition following
maximum uptake of 25 𝜇gGa/1 × 106 cells. However, this
gallium concentration in cells was achieved by loading larger
doses of gallium nanoparticles to cells. Therefore, the use of
GPs provides for more efficient delivery of therapeutic doses
of gallium into macrophages.
It is unclear how gallium blocks HIV infection. As
discussed above, gallium’s similarity to iron may enable it to
interfere with critical enzyme processes during HIV entry,
nuclear localization, integration, and transcription. Here, we
used an HIV-1 pseudovirus carrying a GFP reporter gene
controlled by the LTR promoter and expressed from an
early mRNA. The inhibitory effects of gallium here could
therefore be imparted at any stage during viral entry through
integration and up to the expression of spliced early mRNAs.
GP-Ga2(CO3)3 particles therefore provide a potential
delivery system to block infection of macrophages in vivo.
Macrophages are a major target for HIV-1 infection in
different tissues including the brain [17], lung [25, 26], and
testes [27].The role ofmacrophages duringHIV transmission
is less clear where CD4+ T-cells may form initial targets fol-
lowing sexual transmission [28]. Nevertheless, the potential
of glucan particles for drug delivery at this stage in the form
of microbicides would be attractive to protect against a range
of sexually transmitted pathogens. Future work will address
the characterization of the different phases of gallium trapped
inside GPs in active formulations to correlate and optimize
the effect of the gallium form with its biological activity.
5. Conclusions
We have developed a strategy for the encapsulation of
gallium in glucan particles for targeted gallium delivery into
phagocytic innate immune cells. Gallium was encapsulated
in GPs in the form of gallium nanoparticles of gallium car-
bonate, oxide, or phosphate that are water insoluble at pH 7
providing stability and release gallium from the GPs at pH <5
(endosomal pH). GP-Ga2(CO3)3 formulations showed better
pH 7 stability and pH 5 release profiles, so we evaluated for
their activity to inhibitHIV infection in humanmacrophages.
The GP-Ga2(CO3)3 formulations showed inhibition of HIV
growth up to 95% and higher inhibition than free Ga2(CO3)3
nanoparticles. The use of GPs as carrier of Ga2(CO3)3 into
macrophages therefore provides a potential delivery system
to block HIV infection of macrophages.
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